Who is sponsoring NCT00001239?

NCT00001239 is sponsored by National Cancer Institute (NCI).

What condition does NCT00001239 study?

NCT00001239 studies Breast Cancer, Breast Neoplasms.

What drugs are being tested in NCT00001239?

Interventions: FLAC with GM-CSF.

What is the status of NCT00001239?

NCT00001239 is currently COMPLETED.

Last reviewed 2008-03-03 · How we verify

Combination Chemotherapy (FLAC) Combined With Granulocyte-Macrophage Colony Stimulating Factor in Locally Advanced and Metastatic Breast Cancer

NCT00001239 Phase 2 COMPLETED

To evaluate a dose intensive chemotherapy regimen for the treatment of locally advanced and metastatic breast cancer using granulocyte-macrophage colony-stimulating factor (GM-CSF) to ameliorate chemotherapy-induced toxicity. Combination chemotherapy consists of Flurouricil, Leucovorin, Adriamycin, and Cytoxan (FLAC) which will be given every 21 days for 10 cycles. This protocol will replace the phase I study of this regimen (MB-232/88-C-0207) which found the MTD of this regimen to be at the first dose level. This is a phase II study to determine response rates of this regimen in advanced breast cancer.

Details

Lead sponsor	National Cancer Institute (NCI)
Phase	Phase 2
Status	COMPLETED
Enrolment	100
Start date	1989-07
Completion	2001-01

Conditions

Breast Cancer
Breast Neoplasms

Interventions

FLAC with GM-CSF

Countries

United States